2023 annual financial data
Chemomab Therapeutics 2023 Operating margin
Chemomab Therapeutics 2023 operating margin with verified reported values.
Direct answer
Operating margin was Not calculable.
Operating income was -25,459,000 USD and net income was -24,221,000 USD.
Operating cash flow was -23,550,158 USD.
Get free Chemomab Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 0 USD
- Operating income
- -25,459,000 USD
- Net income
- -24,221,000 USD
- Operating cash flow
- -23,550,158 USD